Biosimilar Antibodies

The Anti-CD3 Antibody (OKT-3) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human CD3. For optimal experimental control, it is recommended to use the Mouse IgG2a kappa Isotype Control. This antibody is pivotal for studies involving T-cell activation and response, making it an essential tool for immunological research.

The Anti-ROBO1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Roundabout Guidance Receptor 1 (ROBO1), playing a crucial role in neural development and axonal guidance. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-CD4 Antibody (Hu5A8) is a humanized IgG4 monoclonal antibody designed to specifically target CD4, a critical molecule involved in the immune response and a key marker on helper T cells. For rigorous experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is optimal for research applications seeking to elucidate the role of CD4 in immune function and pathology.

Velinotamig is a bispecific antibody of the H-γ1_L-κ/H-γ1_L-κ type, designed to target CD3E and TNFRSF17. This antibody facilitates dual engagement, directing T-cell mediated immune responses specifically towards cells expressing TNFRSF17. It is utilized primarily in research focusing on the mechanisms of immune modulation and potential therapeutic strategies for diseases characterized by overexpression of TNFRSF17.

CR-8020 is a human IgG1 monoclonal antibody designed to specifically target the H3N2 subtype of influenza A virus. This antibody recognizes and binds to the hemagglutinin (HA) protein of H3N2 strains, demonstrating potent inhibitory concentrations (IC50) of 3.36 nM and 0.06 nM against A/Brisbane/10/2007 and A/Wyoming/3/2003 strains, respectively. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. CR-8020 serves as a valuable tool for research focused on the immunological response to H3N2 infections and the development of therapeutic strategies against influenza A.

MEDI-2045 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-4Ra/CD124. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Benufutamab (GEN1029) is an agonistic antibody targeting death receptor 5 (DR5), designed to selectively initiate apoptosis in tumor cells. This biologic is composed of two non-competing, DR5-specific IgG1 antibodies, each engineered with an E430G mutation in the Fc domain to enhance its therapeutic efficacy. Benufutamab demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy and apoptosis mechanisms.

Vorsetuzumab, a recombinant human anti-CD70 antibody, targets the CD70 antigen expressed on various tumor cells. This antibody has been shown to enhance macrophage-mediated phagocytosis of renal carcinoma cells and exhibit inhibitory effects on Burkitt’s lymphoma. Vorsetuzumab holds significant potential for therapeutic applications in oncology, particularly in the treatment of renal carcinoma and Burkitt’s lymphoma, by modulating immune responses against tumor cells.

Ciduvectamig is a human IgG4 κ monoclonal antibody targeting CD3E and TMEFF2. For experimental rigor, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity in binding to both CD3E, a key component in T-cell receptor signaling, and TMEFF2, which plays a role in cellular differentiation and proliferation. It is ideal for research applications investigating immune response modulation and cancer biology.

Relfovetmab is a monoclonal antibody that targets nerve growth factor (NGF). This antibody is specifically designed to bind and inhibit NGF, a key molecule involved in the regulation of pain and inflammation. Relfovetmab's mechanism of action makes it a valuable tool for research into pain management and the biological pathways of inflammation.

Blosozumab (LY2541546) is a monoclonal antibody that targets human sclerostin (SOST), functioning as an inhibitor. This antibody promotes bone formation while concurrently decreasing bone resorption, making it a valuable tool in osteoporosis research. Blosozumab is specifically designed to elucidate the pathways and potential therapeutic effects related to bone density regulation and osteoporotic condition management.

Nisfevitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-FZD7 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the Frizzled-7 (FZD7) receptor, a member of the Frizzled family of G protein-coupled receptors involved in the Wnt signaling pathway. The antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focused on the study of Wnt signaling and its role in developmental processes and diseases.

Misitatug is a chimeric antibody of the IgG1κ isotype, specifically designed to target mesothelin (MSLN). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody designed to specifically target TIGIT (T cell immune receptor with Ig domain and ITIM domains). TIGIT serves as an inhibitory immune checkpoint that plays a critical role in immune regulation by promoting NK cell depletion and diminishing cytokine secretion through its interaction with CD155. This antibody has the capability to inhibit effector T cell functions and enhance the regulation of T regulatory cells, contributing to its immunosuppressive effects. Dargistotug is pivotal in studies focused on immune checkpoint blockade and the modulation of immune responses in various diseases.

REGN-7257 is a humanized monoclonal antibody designed to specifically target IL2RG, effectively inhibiting the signaling pathways of all γ-c cytokines. This antibody is particularly useful in research focused on aplastic anemia. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

The Anti-TSPAN8 Antibody is derived from human origin and produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the tetraspanin 8 (TSPAN8) protein. It is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the role of TSPAN8 in cellular processes and disease mechanisms.

Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1β). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1β and 40.8 pM for marmoset IL-1β. Its primary mechanism involves the interruption of IL-1β signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.

Cabotamig is a monoclonal antibody that targets both CD3E and CDH17. This dual-specificity allows for potential applications in modulating immune responses and investigating cellular adhesion processes in cancer research. Cabotamig is designed for use in various experimental settings, including flow cytometry, western blotting, and immunohistochemistry, to study the role of these proteins in immune cell function and tumor biology.

Adintrevimab (ADG 20) is a human IgG1 monoclonal antibody specifically targeting the SARS-CoV (SARS-CoV) virus. This antibody demonstrates inhibitory activity against SARS-CoV-2 variants as well as other SARS-like coronaviruses that possess pandemic potential. This makes it a valuable tool for research into the prevention and treatment of current and future coronavirus outbreaks.

Benralizumab (MEDI-563) is a cytolytic monoclonal antibody that targets the interleukin-5 receptor α (IL-5Rα), facilitating direct, rapid, and near-complete depletion of eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). This agent is specifically designed for the treatment of severe eosinophilic asthma, offering a targeted therapeutic approach by modulating the eosinophilic inflammatory response that characterizes this condition.

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.

Etevritamab is a monoclonal antibody designed to target both CD3E and EGFR. This dual-specificity enables it to engage mechanisms related to T-cell activation and tumor cell inhibition, making it a valuable tool for research in immunotherapy and oncology. Etevritamab may be utilized in studies aiming to elucidate the pathways of immune response modulation and tumor growth suppression.

Ifinatamab is a monoclonal antibody of the immunoglobulin G1-kappa subclass, designed to target and inhibit the human B7 homolog 3 protein (B7-H3). This antibody functions as an immunomodulator, leveraging glycoengineering to enhance its efficacy and stability. Ifinatamab is specifically developed for its potential therapeutic applications in modulating immune responses against various pathological conditions where B7-H3 is implicated.

Barzolvolimab (CDX 0159) is a humanized IgG1 monoclonal antibody targeting the KIT receptor. It demonstrates specificity and potent inhibition of KIT activation mediated by the stem cell factor (SCF). Clinically, Barzolvolimab has been shown to effectively reduce skin mast cell populations and alleviate disease activity in chronic inducible urticaria, highlighting its potential therapeutic application in related pathologies.

ACT017 is a humanized Fab fragment of an anti-GPVI monoclonal antibody designed to inhibit collagen-induced platelet aggregation. This product is specifically developed for research applications focusing on acute ischemic stroke, providing a valuable tool for studies aimed at understanding and potentially intervening in platelet aggregation pathways during ischemic events.

Prafnosbart (DS-6016A) is a humanized monoclonal antibody of the IgG1-kappa isotype, targeting ACVR1 (also known as activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1). This antibody is specifically designed for the study of bone metabolism disorders, providing a crucial tool for researchers investigating the signaling pathways and regulatory mechanisms involved in bone development and maintenance.

Zemocimig is a human IgG4 κ monoclonal antibody targeting coagulation factor F9. For optimal experimental control, it is recommended to use Human IgG4 kappa Isotype Control.

Gresonitamab (AMG 910) is a half-life extended bispecific T-cell engager (BiTE) antibody designed to target CD3-positive T cells and tumor cells expressing CLDN18.2. This antibody facilitates the engagement and activation of T cells at tumor sites, enhancing the immune response against cancer cells. Gresonitamab is primarily utilized in research focused on adenocarcinoma, providing a valuable tool for investigating immune-based therapeutic strategies in this cancer type.

Umesolerbart (REGN5714) is a monoclonal antibody specifically targeting Bet v1, a major allergen from birch trees. This antibody exhibits cross-reactivity with homologous allergens found in alder, hazel, and hornbeam, making it an invaluable tool for studying cross-reactivity patterns in tree pollen allergies. Umesolerbart (REGN5714) is ideal for research applications focused on allergen characterization and the development of therapeutic strategies for pollen-induced allergic responses.

Racotumomab is a recombinant anti-idiotype monoclonal antibody that targets Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other tumor-associated antigens. This antibody has demonstrated efficacy as an active anticancer agent, particularly in the treatment of lung cancer. Its specificity for NeuGc epitopes makes it a valuable tool for research and therapeutic applications in oncology.

Spevatamig is a bispecific antibody of the (H-γ1_L-κ)_(H-γ1_L-κ) type, designed to target CD47 and CLDN18. This dual specificity facilitates its application in the selective targeting and inhibition of pathways crucial in cancer cell survival and immune evasion, making it a valuable tool for research in oncology and immunotherapy.

Tilavonemab (ABBV-8E12) is a humanized monoclonal antibody designed to target and neutralize extracellular pathological tau protein aggregates. It specifically binds to the N-terminal 25-30 amino acid residues of the tau protein. This interaction inhibits the uptake of tau aggregates by human and mouse neurons, mitigates brain volume loss, decelerates the progression of tau pathology, and enhances cognitive functions in transgenic mice models expressing mutant human tau. Tilavonemab is primarily utilized in research focused on Alzheimer's disease, offering significant insights into the mechanisms of tau-related neurodegeneration and potential therapeutic interventions.

The Anti-GC1q R/C1QBP Antibody (60.11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human GC1q R/C1QBP. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control alongside this antibody.

Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody that specifically targets the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody exhibits a high affinity for the extracellular domain of human TIM-3, with a dissociation constant (K_D) of 0.36 nM, indicating strong and specific binding. Surzebiclimab is primarily utilized in the research of cancer immunotherapy, exploring pathways for enhancing immune responses against tumors.

Ozoralizumab (ATN-103) is a humanized trivalent nanobody that targets tumor necrosis factor alpha (TNFα). Comprising two anti-human TNFα nanobodies and one anti-human serum albumin (HSA) nanobody, this antibody is engineered for enhanced stability and serum half-life. It is particularly relevant for research into inflammatory disorders, including various forms of arthritis, where TNFα plays a pivotal role in pathogenesis.

Atrosab is a humanized IgG1 monoclonal antibody that functions as an antagonist to tumor necrosis factor receptor 1 (TNFR1). It effectively inhibits TNF-alpha-mediated apoptosis and the production of interleukins IL-6 and IL-8, key mediators in inflammatory processes. This antibody has been shown to reduce neurological deficits, highlighting its potential utility in the study of neuroinflammation and other inflammatory diseases. For control experiments, the recommended isotype control is Human IgG1 kappa.

The Anti-CD40 Antibody (G28.5) is a chimeric mouse monoclonal antibody of the IgG1 kappa isotype, specifically designed to target human CD40. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of immunological assays investigating the role of CD40 in immune responses and its implications in immunological research and therapeutic development.

TOL-101 is a monoclonal antibody that specifically targets the T-cell receptor (TCR). This antibody is designed for use in the study of T-cell mediated immune responses and may be utilized in various immunological assays to investigate TCR function and expression. TOL-101 is valuable for researchers focusing on cellular immunology, autoimmunity, and the development of immunotherapies.

Guselkumab is a recombinant human IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). This antibody exhibits high affinity for IL-23, with dissociation constants (Kd) of 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 derived from cynomolgus monkeys. By binding to the IL-23p19 subunit, Guselkumab effectively inhibits the production of cytokines that are downstream in the IL-23 signaling pathway. This mechanism of action makes Guselkumab particularly useful in the study of psoriatic arthritis, providing a valuable tool for research into the pathophysiology and potential treatment of this condition.

Xaluritamig is a monoclonal antibody designed to target both CD3E and STEAP1. This dual specificity allows for the potential engagement of immune system modulation through CD3E interaction and direct targeting of STEAP1, a protein implicated in several oncologic processes. Xaluritamig is primarily used in research focused on cancer immunotherapy and the study of immune response mechanisms.

Cliramitug is a monoclonal antibody that specifically targets human transthyretin (TTR). This antibody interacts with TTR, effectively inhibiting its propensity to form amyloid fibrils. By preventing amyloidogenesis, Cliramitug serves as a valuable tool in the study of transthyretin amyloidosis and its associated neurological and cardiovascular pathologies. This antibody is instrumental for researchers focusing on the molecular mechanisms and therapeutic interventions for TTR-related diseases.

Raludotatug is a humanized IgG1-kappa monoclonal antibody targeting CDH6, designed for antineoplastic applications. This therapeutic antibody binds specifically to CDH6, a protein implicated in the progression of certain cancers, thereby inhibiting tumor growth and proliferation. Raludotatug's mechanism of action and specificity make it a valuable tool for research and potential therapeutic interventions in oncology.

Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody targeting vimentin present on the surface of virus-infected cells. It exhibits broad-spectrum antiviral activity and possesses anti-inflammatory properties, specifically mitigating virus-induced inflammation. This antibody is particularly relevant for research focused on severe COVID-19, providing a critical tool for studies aimed at understanding and potentially mitigating the impact of viral infections.

CDX-1401 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets LY75/CD205/DEC-205, a receptor involved in antigen capture and presentation. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody designed for dual targeting of B-cell activating factor (BAFF) and interleukin-17A (IL-17A), exhibiting high affinity with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This antibody is specifically engineered for the study of autoimmune diseases, providing a valuable tool for investigating the pathophysiological roles of BAFF and IL-17A in immune modulation and inflammation.

Brazikumab (AMG 139) is a human IgG2 monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23). It exhibits a high binding affinity with a dissociation constant (K_D) of 0.138 nM for human IL-23. This specificity makes Brazikumab a valuable tool for the study of immune-mediated inflammatory disorders, particularly Crohn's disease.

Paridiprubart (NI-0101) is a humanized monoclonal antibody that targets Toll-like receptor 4 (TLR4). This antibody has been developed for potential application in the research of rheumatoid arthritis, focusing on its role in modulating immune responses associated with the disease. Paridiprubart offers a valuable tool for investigating the pathophysiological mechanisms and therapeutic interventions for rheumatoid arthritis through its specific interaction with TLR4.

Toralizumab (IDEC-131) is a humanized monoclonal antibody targeting CD40 ligand (CD154), composed of human gamma 1 heavy chains and kappa light chains. This antibody selectively binds to CD40L expressed on T cells, effectively inhibiting CD40-mediated signaling. As an immunosuppressive agent, Toralizumab is primarily investigated for its therapeutic potential in systemic lupus erythematosus (SLE) research.

Onvatilimab (JNJ-61610588) is a human IgG1κ monoclonal antibody that targets VISTA (V-domain Ig Suppressor of T-cell Activation), a protein involved in the negative regulation of T-cell responses. This antibody exhibits potent anti-tumor activity by modulating the immune system's ability to recognize and destroy cancer cells. Onvatilimab is primarily researched for its therapeutic potential in oncology, particularly in enhancing immune-mediated tumor suppression.